Kayne Anderson BDC (KBDC) is considered a buy due to its attractive risk-to-reward profile, trading at a 16% discount to book value with a nearly 12% dividend yield and strong dividend safety supported by over 100% net investment income coverage. The portfolio is well diversified, with only 2% exposure to software/technology, reducing risks from AI disruption compared to peers. Key risks include declining debt yields and rising non-accruals, but management expects near-term improvements and favorable sector positioning. Despite recent stock price underperformance, the total return outlook remains positive for dividend investors.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
